Table 4 Factors associated with the recurrence of HCC after DAA treatment in the early phase (within 1 year after DAA treatment completion)
From: AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy
| Â | HCC recurrence | No HCC recurrence | Hazard ratio | 95% CI | p-value |
|---|---|---|---|---|---|
Age (years) | 70.8 ± 8.6 | 71.5 ± 8.1 | 0.99 | 0.96–1.02 | 0.63 |
Sex (male/female) | 41/17 | 56/46 | 1.71 | 0.97–3.02 | 0.064 |
Body mass index (kg/m2) | 23.1 ± 2.8 | 23.3 ± 3.5 | 0.99 | 0.91–1.08 | 0.79 |
White blood cell count (/μL) | 4309 ± 1464 | 4235 ± 1207 | 1.00 | 0.99–1.00 | 0.72 |
Platelet count (×104/μL) | 10.7 ± 5.1 | 11.4 ± 4.6 | 0.97 | 0.91–1.03 | 0.36 |
ALT (U/L) | 51.0 ± 36.2 | 45.4 ± 28.2 | 1.00 | 0.99–1.01 | 0.28 |
AST (U/L) | 55.4 ± 27.7 | 51.1 ± 27.6 | 1.00 | 0.99–1.01 | 0.35 |
Total bilirubin (mg/dL) | 0.8 ± 0.4 | 0.8 ± 0.4 | 1.14 | 0.64–2.00 | 0.79 |
Albumin (g/dL) | 3.7 ± 0.4 | 3.8 ± 0.4 | 0.56 | 0.30–1.04 | 0.10 |
Prothrombin time (%) | 82.1 ± 12.8 | 82.6 ± 16.8 | 0.99 | 0.98–1.01 | 0.82 |
AFP (ng/mL) | 29.3 ± 74.1 | 19.1 ± 46.8 | 1.00 | 0.99–1.00 | 0.30 |
eGFR (mL/min/1.73 m2) | 66.8 ± 20.5 | 69.1 ± 21.0 | 0.99 | 0.98–1.00 | 0.50 |
Total cholesterol (mg/dL) | 150 ± 32.1 | 151 ± 26.8 | 0.99 | 0.98–1.00 | 0.92 |
Diabetes mellitus (no/yes) | 42/16 | 81/21 | 1.44 | 0.81–2.56 | 0.33 |
Alcohol (none/drinking/unknown) | 51/4/3 | 69/12/21 | 0.68 | 0.33–1.39 | 0.29 |
FIB-4 index | 6.6 ± 4.4 | 5.7 ± 3.6 | 1.04 | 0.99–1.10 | 0.33 |
APRI | 1.9 ± 1.8 | 1.5 ± 1.5 | 1.09 | 0.98–1.21 | 0.33 |
Post-treatment white blood cell count (/μL) | 4764 ± 1421 | 4599 ± 1576 | 1.00 | 0.99–1.00 | 0.52 |
Post-treatment ALT (U/L) | 21.2 ± 9.2 | 24.1 ± 29.4 | 0.99 | 0.97–1.01 | 0.47 |
Post-treatment AST (U/L) | 29.1 ± 9.8 | 29.9 ± 19.5 | 0.99 | 0.97–1.01 | 0.76 |
Post-treatment total bilirubin (mg/dL) | 0.9 ± 0.4 | 0.8 ± 0.3 | 1.15 | 0.61–2.18 | 0.65 |
Post-treatment albumin (g/dL) | 3.8 ± 0.5 | 3.9 ± 0.3 | 0.63 | 0.34–1.16 | 0.29 |
Post-treatment prothrombin time (%) | 82.5 ± 14.3 | 83.9 ± 17.2 | 0.99 | 0.98–1.01 | 0.62 |
Post-treatment AFP (ng/mL) | 11.9 ± 15.5 | 6.4 ± 6.3 | 1.04 | 1.02–1.06 | 0.028 |
Post-treatment eGFR (mL/min/1.73 m2) | 63.5 ± 18.2 | 67.9 ± 19.8 | 0.99 | 0.97–1.00 | 0.19 |
SVR/no SVR | 48/10 | 98/4 | 2.85 | 1.43–5.64 | 0.007 |
Child-Pugh class (A/B/C) | 46/9/1 | 83/13/0 | 1.46 | 0.77–2.75 | 0.37 |
BCLC stage (0/A/B/C/D) | 18/16/14/10/0 | 44/24/13/19/2 | 1.10 | 0.89–1.37 | 0.22 |
Number of months from HCC treatment to DAA therapy initiation | 12 ± 14 | 23 ± 26 | 0.99 | 0.99–0.99 | 0.001 |
Number of curative treatments for HCC | 1.7 ± 1.7 | 0.8 ± 1.3 | 1.25 | 1.10–1.41 | 0.001 |